



HHS Public Access

Author manuscript

Diabetes Res Clin Pract. Author manuscript; available in PMC 2019 November 01.

Published in final edited form as:

Diabetes Res Clin Pract. 2018 November ; 145: 39–50. doi:10.1016/j.diabres.2018.04.004.

Nutrition Therapy Within and Beyond Gestational Diabetes

Teri L. Hernandez, PhD, RN^{1,2}, Archana Mande, MS, RD³, and Linda A. Barbour, MD, MSPH^{1,4}

¹Department of Medicine, Division of Endocrinology, Metabolism, and Diabetes; University of Colorado, Anschutz Medical Campus, Aurora, CO

²College of Nursing; University of Colorado, Anschutz Medical Campus, Aurora, CO

³Colorado Clinical and Translational Science Institute, University of Colorado, Anschutz Medical Campus, Aurora, CO

⁴Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, University of Colorado School of Medicine, Aurora, CO

Summary

With the global rising prevalence of gestational diabetes (GDM), an adaptable, economical approach to nutrition therapy that effectively controls maternal glycemia while promoting normal fetal growth will have far-reaching implications. The conventional focus has been to rigidly limit all types of carbohydrate. While controlling glucose, this approach fosters maternal anxiety and is a primary barrier to adherence. Many mothers substitute fat for carbohydrate, which may unintentionally enhance lipolysis, promote elevated free fatty acids (FFA), and worsen maternal insulin resistance (IR). Nutrition that worsens IR may facilitate nutrient shunting across the placenta, promoting excess fetal fat accretion. Evidence suggests that liberalizing higher quality, nutrient-dense carbohydrates results in controlled fasting/postprandial glucose, lower FFA, improved insulin action, vascular benefits, and may reduce excess infant adiposity. Thus, a less carbohydrate-restricted approach may improve maternal adherence when combined with higher quality carbohydrates, lower fat, appropriate caloric intake, and ethnically acceptable foods. Such a diet can be culturally sensitive, socioeconomically attentive, minimize further weight gain in GDM, with potential relevance for pregnancies complicated by overweight/obesity. Future research is needed to better understand the effect of macronutrient composition on the placenta and gut microbiome, the benefits/risks of nonnutritive sweeteners, and whether precision nutrition is beneficial in pregnancy.

Keywords

Pregnancy; Gestational diabetes; Obesity; Nutrition; Diet

Corresponding Author: Teri L. Hernandez, PhD, RN, Associate Professor of Medicine and Nursing, Division of Endocrinology, Metabolism, and Diabetes, College of Nursing, 12801 E. 17th Avenue, MS8106, Aurora, CO 80045, Phone: (303)724-3943, Fax: (303)724-3920, teri.hernandez@ucdenver.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Introduction

The high prevalence of obesity in young women has changed the pregnancy landscape to one commonly characterized by over-nutrition. Over the first and second decades of the female lifespan, key metabolic factors and behaviors contribute to insulin resistance (IR) and glucose intolerance, often manifesting in pregnancy. This risk begins with a high birthweight or excess adiposity, followed by accelerated postnatal growth potentially promoted by formula feeding, leading to early adiposity rebound, childhood overweight or metabolic syndrome. This phenotype is subsequently compounded by years of poor diet quality, over-nutrition, a sedentary lifestyle and poor sleep[1] resulting in worsening puberty IR that does not normalize[2] after adolescence. By young adulthood, these influences culminate in a prepregnancy phenotype characterized by obesity and pre-existing IR, where mild hyperglycemia and hyperlipidemia are already present, only to manifest and be amplified with superimposed pregnancy metabolic adaptations[3].

Seminal leaders in the field of diabetes in pregnancy recognized that fetal overgrowth is a primary concern in pregnancies affected by diabetes[4], and Freinkel[5] advocated that lessons from diabetes in pregnancy apply to all pregnancy. Twenty-five[6] to nearly 40%[7] of young women are obese worldwide, and although women with obesity alone account for the highest number of pregnancies complicated by fetal overgrowth[8], nutrition therapy is instituted only once gestational diabetes mellitus (GDM) has been diagnosed. However, as more women are diagnosed with GDM accompanied with milder degrees of hyperglycemia[9], now estimated at ~20% of pregnancies[10], more overweight and obese women will qualify for the diagnosis. Nutrition therapy is the single management component applicable to every woman with the GDM diagnosis, regardless of phenotypic severity. Although the optimal approach to nutrition therapy remains elusive and may require a personalized strategy, it is critical to identify therapeutically efficacious components that minimize the need for medical therapy in this growing population of mothers. Further, adaptable, economical options effective for GDM might impart benefits for mothers who are overweight or obese, who often share a milder metabolic phenotype and deliver the largest number of large-for-gestational age (LGA) infants[8].

Over a century of clinical experience supports dietary manipulation in the treatment of diabetes[3, 11], thus the conventional approach to treatment of GDM is restriction of carbohydrate[4]. In GDM, restriction of carbohydrate, particularly simple carbohydrate, reduces postprandial hyperglycemia and decreases fetal glucose exposure, reducing fetal overgrowth[12]. Unfortunately, the restrictive approach to nutrition has been identified as the primary barrier to treatment adherence in GDM[13]. Moreover, there is a lack of evidence supporting all carbohydrate restriction in GDM[14, 15] and concerns focused on its unintended consequences have been raised[15–17]. In environments that promote over-nutrition and reduced physical activity, with rigid carbohydrate restriction comes a tendency to replace carbohydrate calories with those from fat. We[18, 19] and others[17, 20–28] have shown that maternal lipids (triglycerides [TG], free fatty acids [FFA]) are positively associated with excess fetal growth and that high total and saturated fats, which increase FFA exposure, can worsen maternal IR resulting in prolonged hyperglycemia. Although

there remains a critical need for RCTs designed to understand the physiologic effects of nutrition in GDM[14, 16], the purpose of this paper is to illuminate the high potential for a less restrictive but higher-quality macronutrient approach to choices in nutrition therapy. Evidence from RCTs in GDM suggests this approach may effectively optimize intrauterine conditions and fetal growth patterns, potentially applying to obesity and all pregnancies.

Targeting Metabolism in Pregnancy using Nutrition

It has been recognized for decades that in-utero conditions are formed by maternal nutrition[5]. Orchestrated by placental hormones, normal pregnancy metabolism is characterized by reduced insulin sensitivity, increased postprandial glucose[29], 2–3 fold increased insulin production[30, 31], and increased plasma FFA, TG, total cholesterol and phospholipids[31–33]. When fetal growth increases in the 3rd trimester, IR heightens with each gestational week to ensure nutrient shunting to the fetus[34–36]. Pre-conception obesity is commonly associated with impairments in insulin-stimulated glucose uptake, insulin-suppression of hepatic gluconeogenesis, and insulin-suppression of lipolysis that intensify by the third trimester[33, 37, 38]. In fact, nearly 50% of GDM in the United States can be explained by overweight/obesity[39], and is a result of a combination of IR and insufficient beta cell reserve[31, 40].

Recently, we demonstrated that women with diet-controlled GDM randomized to a higher-complex carbohydrate, lower fat diet (vs. carbohydrate restriction with higher fat) demonstrated greater insulin action after 6–7 wks of provided diet. The estimates of IR across both groups were strongly correlated with infant adiposity[41] (Figure 1). Although women with GDM have higher patterns of glycemia[42, 43], we have shown using eucaloric fixed diets that healthy obese women also have higher patterns of 24-hr glycemia than normal-weight mothers (by ~9%, using continuous glucose monitoring) early and later in pregnancy[18, 19]. Fasting TG are higher in GDM throughout gestation compared to obese and normal-weight women[44]. However, in our controlled studies (all meals were provided), meal studies at 28–31 wks gestation demonstrated *postprandial* TG were similar in diet-controlled GDM (interventional study)[45] and otherwise healthy obese mothers without GDM (controlled observational study)[19]. Although nutrition therapy in GDM has focused on control of maternal glycemia[12], mounting data suggest that maternal lipids, especially TG, may be stronger drivers of fetal growth than glucose in GDM[21, 28] and in pregnant women with normal glucose tolerance[17–20, 22–28]. In our studies of obesity alone, both fasting and 1-hr postprandial TG at only 16wks gestation were strongly associated with neonatal adiposity[19], and more so than maternal glucose. Maternal TG can be hydrolyzed to FFA by placental lipoprotein lipase (pLPL), increasing FFA availability to the fetus for fetal fat accretion. We have recently shown that pLPL activity correlates with newborn fat mass[46]. Maternal glucose, FFA, and TG, factors driven by maternal IR, are sensitive to nutritional patterns (Figure 1). Therefore, these data highlight the potential of nutrition therapy to target maternal glucose *and* TG or FFA to mitigate fetal overgrowth in GDM, potentially extending to overweight and obesity outside of GDM.

Glycemic Index and Higher Quality Carbohydrates

Glycemic index is a property of a carbohydrate food that describes its ability to raise blood glucose: a low-GI food has a lesser ability to raise postprandial glucose, while high-GI foods acutely raise blood glucose[47]. Lower-GI foods produce higher satiety, while higher-GI foods are associated with increased hunger, insulin levels, and energy intake[47]. Over the last decade, low-GI foods have been increasingly recommended for nutrition in pregnancy[48]. Freinkel[5] demonstrated that the postprandial glucose increases the maternal-fetal glucose gradient, facilitating placental glucose transport. Because postprandial glycemia is higher with heightened IR and impaired glucose tolerance (i.e., obesity, GDM, pre-existing diabetes), low-GI foods have high potential to help reduce the risk of LGA/macrosomia[48]. Glycemic load (GL) describes the insulin demand created by a carbohydrate food[49]. When considering a less restrictive approach for carbohydrate intake in GDM, international consensus supports that complex carbohydrates should be of higher quality[47, 50] to reduce insulin demand. A nutrition pattern including *higher quality* carbohydrates liberalizes those that tend to be nutrient dense (more vitamins/minerals), have higher fiber, and are lower in calories and GI/GL[47, 50–52].

Anxiety and Fear Undermine Nutrition Therapy in GDM

A diagnosis of GDM generates anxiety and fear. At ~28 wks gestation, the diagnosis is often a surprise to women, who until then perceived a normal pregnancy[53]. Quite suddenly, the pregnancy is 'high-risk'; women are asked to self-monitor blood glucose, conform to a rigid restriction of dietary carbohydrate, read food labels and count grams of carbohydrate, attend more doctor visits, and they face the potential for treatment with insulin and increased fetal surveillance. The need for insulin has been associated with feelings of failure, guilt[54], and anxiety[55]. Once the diagnosis is assigned, women have reported fear for the baby's wellbeing, anxiety and depression[53, 55]. They have expressed that nutrition therapy is culturally insensitive[54–56], intrusive[53], and hard to follow late in pregnancy[53, 57, 58]. In particular, food selection is mentally exhausting[57]. In general, a restrictive approach to diet creates internal conflict and a focus on prohibited foods[59]--a mindset that undermines weight and nutrition interventions. On the other hand, a less restrictive approach allows a range of acceptable foods, alleviating the feeling of rigid control and inner conflict, and instead allowing a range of acceptable foods. A flexible, less restrictive approach has been associated with better health/psychological well-being, higher self-confidence, and commitment to personal health goals, all of which predict success for nutrition programs[59].

In the authors' clinical experience, some women are so fearful of macrosomia that they consume extreme carbohydrate-restricted diets, freely consuming fat instead, reasoning that less will improve infant outcomes. Although their glycemia is typically controlled, they are anxious, unhappy, and consume only a narrow range of suitable foods and are at risk for ketosis. Others are so stressed by the nutrition plan that they simply do not follow it, and consistent with recent experience in China[58], self-monitoring of glucose is less than recommended as it provides feedback of their perceived failure. A less restrictive approach

to nutrition therapy in GDM could increase self-confidence, compliance, and avoid compensatory higher fat intake.

Unintended Consequences: Carbohydrate Restriction in GDM

Rather than limiting all carbohydrate, a focus on which macronutrients might influence maternal IR may be an alternative and beneficial approach. This is based on the premise that the degree of IR increases fetoplacental nutrient exposure (glucose, lipids, amino acids)[5] (Figure 1). We have demonstrated that pregnancy-induced IR can be attenuated by a lower fat diet[41, 45] and excessive fetal growth might be favorably modified using a liberalization of high-quality carbohydrates with lower fat[13, 41, 45, 60]. Because amplified maternal IR and lipolysis are fundamental adaptations to maternal physiology, dietary manipulations that increase FFA (which interfere with insulin signaling[61]), may actually result in protracted hyperglycemia due to increasing IR. If carbohydrate energy is replaced by fat, given that it is difficult and not advantageous to increase protein to 20%, there is potential for increased peripheral and hepatic IR, a finding supported in human studies[41, 62]. Recently, pre-conception carbohydrate restriction was linked to a higher incidence of neural tube defects, probably due to lower intake of nutrient-fortified foods with folic acid[63]. Outside of pregnancy, rigid carbohydrate restriction (20g/day) with high fat intake resulted in blunted 24-hr insulin secretion and worsening IR. This was accompanied by sustained elevated FFA over 24hrs and very low insulin levels were inadequate to suppress lipolysis [64]. These conditions associated with high dietary fat intake suggest increased IR that, in pregnancy, would promote in-utero over-nutrition, setting the stage for overgrowth (Figure 1).

Lipids and FFA are potent fetal growth substrates now also recognized to have negative intrauterine programming effects associated with excess fetal growth and poorer long-term offspring health[65]. Intensified carbohydrate restriction to minimal intake carries a risk for maternal ketosis[66] from increased lipolysis and generation of FFA (Figure 1). With severe carbohydrate restriction, the obligate fetoplacental glucose supply which depends on higher maternal glucose, could challenge placental-fetal glucose transfer [67]. Pregnant women are advised to consume an average of 175g of carbohydrate/day, which includes the necessary 33g to support fetal brain development[68]. However, newer evidence suggests the recommended ~175g/day does not account for *placental* glucose requirements, which likely exceed 135g alone in the 3rd trimester in a NW mother and would be increased with higher BMI[67]. Extremes in protein intake should also be carefully considered as both restricted and excessive protein intake have been associated with low birthweight[69, 70]. Differential effects of dietary carbohydrate on postprandial glucose[71] support that although simple carbohydrates acutely raise blood glucose[47], complex nutrient-dense carbohydrates (polysaccharides and starches primarily from grains, vegetables, and legumes)[50] result in an attenuation of the postprandial glucose excursion[29]. With optimal dietary carbohydrate and lower fat intake, nutrition therapy could safely support a less restrictive plan that meets glycemic targets, weight stabilization goals[72], supports appropriate fetal growth, and, importantly, avoids the need for medication and expensive fetal surveillance.

Evidence Supporting Less Restrictive Carbohydrate Intake for GDM

Effects on Maternal Glucose Metabolism

Treatment of GDM has aimed to keep maternal glucose within treatment targets of: fasting 90–95 mg/dL, and 140 or 120 mg/dL for 1- and 2-hour postprandial glucose, respectively[3, 9]. Women who attain a fasting glucose \leq 95 mg/dL within 2 weeks of diet prescription are less likely to require insulin or oral hypoglycemic therapy[73, 74]. Two highly controlled randomized crossover studies (all food provided) showed that nutrition with 60–70% of total intake from higher-quality complex carbohydrates controlled postprandial glucose to within treatment targets within 3 days (n=4 women)[45] and 4 days (n=16)[75]. Although maternal glucose control in the former study might in part be explained by fiber intake (70g fiber, 70% carbohydrate vs. 31g, 35% carbohydrate)[75], fiber was similar in the latter study (29g, 60% carbohydrate vs. 24g, 40% carbohydrate)[45]. In the latter study, performed by our group[45], the 24-hr glucose area-under-the-curve (AUC) by continuous glucose monitoring (CGM) was minimally higher by 6% on the 60% higher complex carbohydrate diet (vs. 40% carbohydrate), but both diets controlled maternal glycemia to well below therapeutic targets. In Poland[76], it was similarly demonstrated within a 60% total carbohydrate diet group that postprandial glucose was lower than baseline after 2 weeks. In Iran, women were randomized to a dietary approach to stop hypertension (DASH, low-sodium) diet (~65% carbohydrate, mainly complex) vs. a ~55% carbohydrate diet. Although women with GDM demonstrated a decreased fasting glucose[77] and improved response to an oral glucose tolerance test[78], the findings are surprising given the intervention was only 4 weeks, immediately after GDM diagnosis, and was not maintained for the last 8–10 weeks of pregnancy.

In our study, we examined the glucose and FFA response after 6–7 weeks of diet and until delivery (all meals were provided to the mothers). Surprisingly, women randomized to the complex carbohydrate diet (60% of total calories, similar in carbohydrate, sugars and fiber to DASH) actually had a *decrease* in fasting glucose while those randomized to the lower-carbohydrate (40% of total calories) diet demonstrated *increased* fasting glucose. In these trials, protein ranged 15–20%, and total fat was lower (10–25%) with lower saturated fat in the higher carbohydrate arm. The lower total fat content could have added to beneficial effects on glucose metabolism due to lessened FFA-induced worsening of IR[79]. Overall, these trials underscore that women with GDM achieved good glycemic control with a less carbohydrate-restrictive approach to nutrition therapy.

Effects on Lipids, Insulin Resistance, Inflammation

In the short-exposure randomized crossover studies, the higher complex carbohydrate diets resulted in lower fasting total cholesterol, fasting FFA (70% carbohydrate/10% fat)[75], and postprandial FFA response to a controlled meal (60% carbohydrate/25% fat)[45], which may attenuate IR. Women who consumed the DASH diet (65% carbohydrate/18% fat) for only 4 wks appeared to have a lower lipids, HbA1c, systolic blood pressure[78], increased total glutathione and antioxidant capacities, as well as an improved IR index (HOMA-IR)[77], presumably from consuming more nutrient-dense carbohydrates with increased vitamins and minerals. However, there was no evidence that the mothers actually consumed this diet by

urinary sodium or other biomarkers. Further, the intervention was not maintained for the remaining 8–10 weeks of pregnancy and the women were not directly followed, warranting caution in the interpretation of the results[77, 78]. In our study[41], we biopsied maternal adipose tissue and demonstrated a nearly doubled suppression of isoproterenol-stimulated lipolysis (56% suppression), a biomarker of adipose tissue IR, in those following the higher complex carbohydrate diet (60% carbohydrate/25% fat) compared to only 31 % suppression in the lower carbohydrate (40% carbohydrate/45% fat). Adipose tissue gene expression in mothers on the higher complex carbohydrate/lower fat diet also suggested less inflammation, although in this small study we did not show decreased plasma inflammatory biomarkers[41]. These data suggest better insulin action in adipose tissue with the more liberal complex carbohydrate (with lower fat) exposure after 6–7 wks. Overall, the studies suggest that less restrictive higher-quality complex carbohydrate with lower total fat, possibly lower sodium and higher antioxidant activity, lowered FFA and improved insulin action despite the inevitable increase in pregnancy-induced IR.

Effect on Gestational Weight Gain (GWG)

It has been suggested that a 50–60% carbohydrate diet leads to excessive GWG and postprandial hyperglycemia[80], which fuels a focus on rigid carbohydrate restriction in GDM. Weight gain might be expected in the setting of caloric excess and high consumption of simple carbohydrates that acutely increase blood glucose, where higher insulinemia would promote lipid storage[81]. In Spain[82], women randomized to a low-carbohydrate (40% carbohydrate/40% fat) gained 1.4 kg vs. 2.3 kg in the control group (55% carbohydrate/25% fat). However, only total GWG was reported and weight gained during the intervention is unclear. In Australia[83], 42% of those in a higher-GI group had excessive GWG[84], compared to 25% of women randomized to low-GI. Again, only total GWG was reported and weight gained before the intervention is unknown. The higher proportion of insulin therapy in both groups could further confound the GWG observation because insulin administration is clearly associated with weight gain. Even more of a confounder is if mothers consume more carbohydrate in order to avoid hypoglycemia from too much insulin administration. Three trials have reported weight gained during the diet intervention[41, 77, 78, 85], which was ~1–2 kg on either a higher- or lower-carbohydrate eucaloric diet, supporting that a less restrictive consumption of complex, lower-GI carbohydrates does not promote excess GWG.

Need for Insulin Therapy

Historically, non-randomized studies in GDM demonstrated that glycemic control could be achieved using diet+insulin[4], and consumption of <42% carbohydrate might avoid the need for insulin therapy[86]. Two published RCTs were powered on the need for insulin. In Australia[87], 29% of women randomized to a low-GI diet (GI=48) required insulin versus 59% with a higher-GI diet (GI=56). In fact, 50% of women who failed the higher-GI diet were able to avoid insulin by switching to the low-GI option. Fiber was similar in the low-GI (26g) and high-GI (23g) arms. In Spain[82], 55% of women randomized to a low-carbohydrate (~40% carbohydrate/40% fat) or a higher carbohydrate diet (~55% carbohydrate/25% fat) required insulin, showing no difference. Intakes of total energy, fat and protein were not reported. Women did not decrease simple sugar intake over the 6–12

wk intervention in either group. In the DASH diet studies, fewer women randomized to DASH for 4 wks (65% carbohydrate/18% fat vs. 54% carbohydrate/28% fat) required insulin; however, this is curious given the intervention was not continued for the last 8–10 weeks of pregnancy. Overall, the data support that in GDM, less restrictive intake of higher quality low-GI carbohydrates can potentially reduce the need for insulin therapy.

Effect on Maternal and Infant Outcomes

Two published RCTs were powered on a difference in infant birth weight. An Australian RCT (n=92)[83] designed to compare the impact of a low-GI diet with 27g fiber (GI=47, 37% carbohydrate/33% fat) to a higher-GI diet (GI=53, 40% carbohydrate/35% fat) with similar fiber on infant birth weight (powered on 260g difference) was stopped early because a difference in birthweight remained undetectable between groups; neither group met the GI targets. Although in the Iran[85] DASH vs. control trial, a lower birth weight was reported with DASH, this was an unusually large difference (3223g vs. 3819g) given the sample size was only 58, the intervention was only 4 weeks duration, and the women were simply sent back for routine care by their individual providers for the remaining 8–10 weeks of pregnancy. Our data[41] (all food was provided) supported a trend for lower infant adiposity in women randomized to the higher complex carbohydrate (lower fat) diet for 6–7 wks through delivery.

Birthweight and infant adiposity at birth, however, are not the only important outcomes GDM, obesity, or diet may affect. Our group recently demonstrated that infants from obese GDM mothers were born with 68% more intrahepatic lipid at 2 weeks of life. This underscores concerns about excess FFA availability to the fetus, who early in pregnancy has insufficient subcutaneous fat and may store excess energy as visceral fat[88]. Excess intrahepatic lipid could serve as a “first hit,” increasing later risk for non-alcoholic fatty liver disease (NAFLD), present in 40% of obese children and the leading cause of liver transplant[89].

Effect of Fiber and Low-GI Diets

It is difficult to isolate the independent effects of fiber and low-GI diets since both are often manipulated when trying to influence each separate component. One RCT formally compared a high-fiber (80g fiber/ 60% carbohydrate/20% fat) to a lower-fiber (20g fiber/50% carbohydrate/30% fat) diet in GDM. However, women self-monitored their glucose only 2 days/wk, self-reported compliance was poor (40–60%) due to GI intolerance (high-fiber goal was 80 grams), and the drop-out rate was unreported. In the early short-term crossover study[75] fiber intolerance was also described (70g fiber/70% carbohydrate vs. 31g fiber/35% carbohydrate), but the improvement in glycemic control could be due to differences in carbohydrate, fat, or by higher fiber. Viscous fiber is thought to attenuate postprandial glycemia due to its absorptive properties[90]. In Type 2 diabetes, this concept was recently supported whether the source of fiber was dietary or by supplementation[91]. Outside of pregnancy, controlled studies have also shown that glycemic load (total insulin demand) is a stronger driver of glycemic response in single foods and mixed meals than total carbohydrate or fiber[29, 92, 93]. Across the remainder of RCTs in GDM[41, 45, 78, 82, 83, 85, 87, 94, 95], the difference in fiber between higher- and lower carbohydrate diets was so

small (2–7g) that it was unlikely to explain improved glucose tolerance. Higher-quality complex carbohydrates tend to have higher fiber content if they are from vegetable, legume, or whole grain sources, and higher fiber diets are linked with lower cancer, diabetes and CVD risk[47, 96]. By meta-analysis, there was a suggestion that increased fiber intake alone could influence fetal growth; a low-GI diet with higher fiber alone (vs. low-GI with lower fiber) in pregnancy reduced the risk for macrosomia[97].

In support of low-GI nutrition patterns, the aforementioned meta-analysis of 5 RCTs[97] showed that in addition to reducing the need for insulin, a low-GI diet (vs. higher-GI) in GDM reduced the risk of macrosomia. In China[95], Asian women with GDM and a much lower BMI of 20–21 kg/m² admitted to a metabolic ward were randomized to 4-days of either replacement of rice in meals with a low-GI staple food (brown rice) vs. control (white rice)(total carbohydrate/energy content held constant). Women randomized to the low-GI staple had decreased fasting glucose (–3.7% vs. –1.2%, respectively) and a greater reduction in postprandial glucose (–19 to –22% vs. –7 to –12%, respectively). Overall, the studies suggest a benefit of low-GI diets in GDM on fasting/postprandial glucose and infant birthweight, particularly when fiber intake is increased.

Outside of pregnancy, mounting evidence supports low-GI/low-GL diets with higher-quality carbohydrates for control of postprandial glycemia in obesity and impaired glucose tolerance[47]. In pregnant mothers *without* GDM, a recent meta-analysis of 11 trials demonstrated that a low-GI diet (vs. control) was associated with a reduction in fasting and postprandial glucose, and LGA[98], although the trials were highly heterogeneous. In mothers with either GDM or impaired glucose tolerance a low-GI (vs. high-GI) diet resulted in a higher percentage of postprandial glucose values in the target range, but there was no significant difference in glycemia between groups[99]. In 800 pregnant women at risk for macrosomia[100], women randomized to a low-GI (vs. high-GI diet) had lower GWG by 1.5kg, less incidence of a higher fasting glucose (>92 mg/dL) or a 50g glucose challenge >140mg/dL[101] but no significant difference in infant birthweight. In Australia, in women at risk for GDM, a low-GI diet did not produce a difference in pregnancy outcomes[102] although in a subgroup analysis of women who appeared to be able to slightly reduce GI, the *offspring* had slightly lower birthweight/length z-scores with evidence of lower aortic intima-medial thickness at 12 months of life[103]. As a whole, the evidence implicates low-GI diets in improved postprandial glucose, insulin action, and vascular health, with reduced GWG. These benefits may be linked to increased consumption of higher-quality complex carbohydrates, which overall are lower in GI, may contain higher fiber, are more nutrient dense[104] and have been linked with greater satiety[47].

Unknown or Poor Compliance in Nutrition Therapy for GDM

Compliance to nutrition therapy in GDM remains one of the largest confounding factors across studies[16]. To increase compliance, investigators have implemented strategies where all food is provided to participants[41, 45, 75, 95], a sample food basket is provided[83], and phone follow-up, meetings with a registered dietitian, and menus for participants to follow were used. Compliance has been measured with scoring tools using a questionnaire, and self-reported intake (food records). Despite these strategies, compliance continues to

undermine trial outcomes[15]. In the RCT where fiber was manipulated, there was no difference in glycemic control but compliance marginally despite being reported as “good” when only 60% self-reported compliance and “acceptable” when only 40% reported compliance and there was significant attrition[105]. In Poland[94] a 60% to 45% total carbohydrate content was compared and although improved glycemic control within groups was reported, self-reported compliance was ~50%. Despite providing sample food baskets, participants in the Australian RCT of low- vs- higher-GI diets failed to achieve the GI targets[83], resulting in little difference between diets (GI: 53 vs. 47), likely explaining the negative trial outcome. In Spain[82], where higher vs. low-carbohydrate diets were compared, about 2/3 of women returned diet records, only the low-carbohydrate group reported they met the carbohydrate target, and attrition within the control group was 20%. In the 4-week DASH studies, urinary sodium was not included as a compliance metric[77, 78, 85]. Even in our study where food was provided for 6–7 wks through delivery[41, 45], full compliance cannot be guaranteed. These illustrations demonstrate the critical need to consider compliance as a major factor in the interpretation of trial outcomes, especially when self-reported by questionnaires. Trials that provide all meals, as in our pilot RCT[41, 45](larger trial ongoing), are likely to be the most rigorous method to maximize compliance, but is expensive and labor intensive.

Cultural Adaptability of a Less Restrictive Approach to Nutrition Therapy in GDM

For an approach to nutrition therapy in GDM to be truly optimal, it must be adaptable and economical (Table 1). One of the leading factors that undermines nutrition therapy in GDM is its cultural unacceptability[54–56]. Linked to a restrictive approach, women believe they cannot consume many foods consistent with their regional culture. Clearly, different regions of the world have varied dietary patterns defined by local food availability, cultural/traditional practices, and socio-economic factors. Consequently, dietary recommendations must vary across the globe to suit the local dietary patterns. In Table 1, we offer examples of foods that are culturally sensitive which can be incorporated in nutrition approaches for GDM across wide-ranging ethnic populations. The global nutrition transition, mainly affecting the developing parts of the world such as Asia, Latin America and Africa, is causing a shift from traditional diets to patterns of eating that highly depend on processed foods, high fat/high caloric meals, and eating away from home[106]. A consequent increase in incidence of non-communicable diseases, such as obesity and diabetes, is posing major health and economic challenges in these relatively poor parts of the world.

Dietary interventions from across the globe suggest beneficial effects of traditional foods high in complex carbohydrates and fiber, with lower GI and that are low in fat. In a study with immigrant GDM mothers in Italy, an ethnic meal plan resulted in better maternal and fetal outcomes than a standard meal plan, due to better adherence to ethnic foods[107]. Outside of pregnancy in Type 2 diabetes, a rice and beans combination was found to be effective in controlling postprandial glycemia when compared to rice alone[108]. Similarly in Asia, a brown rice-based Vegan diet yielded greater reductions in HbA1C when compared to conventional diet [109]. Also in a Type 2 population in India, a millets-based regional

dish was shown to significantly reduce postprandial glycemia compared to its rice-based counterpart [110]. These foods have not yet been tested in studies of GDM women. Adherence to a prescribed therapeutic diet is hindered by many barriers including elimination of culturally familiar foods and a perceived inability to eat same food as the rest of the family[111, 112]. Hence, a promising dietary approach in GDM would be the one that targets an optimal maternal weight goal and is delivered in the form of culturally sensitive foods, potentially improving patient acceptability and adherence to these diets.

Conclusions and Recommendations

Nutrition therapy is the single treatment component that will reach every woman with GDM across diagnostic criteria. Despite the advancing IR of pregnancy, the evidence to date suggests that an optimal mixture of higher-quality complex carbohydrates with less glycemic potential, lower fat, and appropriate protein supports good glycemic control and insulin action, improves lipemia, and may have beneficial vascular effects. A less carbohydrate-restrictive approach to nutrition therapy in GDM can be adapted to fit cultural diet preferences, lessening diagnosis-provoked anxiety, boosting compliance, and avoiding unintended consequences associated with compensatory higher fat intake. Low-GI diets may reduce the need for insulin and lessen postprandial hyperglycemia. Future prospective RCTs are suggested to include: use of provided foods; consistent reporting of total GWG vs. weight gained during intervention; inclusion of infant adiposity as a marker of in-utero nutrition exposure given its better prediction of childhood obesity than birthweight[113]; control of confounders such as medication, disparate energy intake, and physical activity between diets; improved biomarkers of dietary adherence; inclusion of homogeneous samples of women (ethnicity, glucose metabolism)[3, 40]; reporting of achieved glycemia[3]; and more reliable reporting of foods consumed. Data suggest that women with GDM do not require any additional weight gain for adequate fetal growth[72]. Appropriate focus on minimizing additional weight gain by prescribing eucaloric diets is essential.

Nutrition directly affects the maternal gut microbiome, which is passed to the infant and has been shown to promote an obesigenic phenotype with a high fat simple carbohydrate diet[114]; extensive research is underway and will likely be highly informative. Additionally, there is speculation that a higher fat, high simple sugar diet that leads to excess FFA availability to the fetus could result in increased intrahepatic lipid stores and potentially increase the risk of NAFLD[89], underscoring the need for offspring measures beyond birthweight or percent fat at birth. The use of non-nutritive sweeteners have recently been linked with later obesity risk and poor cardiometabolic health[115]. Because women with GDM are typically counseled to substitute sugar with non-nutritive sweeteners, how the use of these products impact the gut microbiome in pregnancy and maternal and infant outcomes remains unstudied but is critically important. Identifying a diet the optimal diet for GDM mothers is likely to apply to mothers with obesity, from which the largest numbers of LGA infants are born. Importantly, earlier adoption of a healthier diet in pregnancy may be critical to improve pregnancy outcomes given fetal hyperinsulinemia occurs by 16 weeks, placental transporters are likely to be set early in pregnancy, and exposure to high levels of free fatty acids before fetuses develop later subcutaneous fat depots could result in increased

visceral or hepatic fat. More study on how particular macronutrients directly affect placental function and transport are needed.

The evidence to date supports a less restrictive approach including higher-quality complex carbohydrates, but lower fat, which may be adopted beyond the window of GDM by the mother and her family, serving as a foundation for a lifetime higher diet quality in mother and offspring[70]. Newer research in personalized medicine may revolutionize our ability to optimize nutrition therapy in GDM. However, until this is achievable, we can at least attempt to maximize cultural adaptability, better address the socioeconomic considerations, and adopt a less restrictive approach that allows greater flexibility in choosing healthier foods designed to stabilize weight and promote good metabolic health far beyond the gestational window.

Acknowledgments

Funding Acknowledgement: This work is supported by the National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease, R01 DK101659

References

1. Baidal JA, Taveras EM. Childhood obesity: shifting the focus to early prevention. *Arch Pediatr Adolesc Med.* 2012; 166:1179–81. [PubMed: 23108905]
2. Kelsey MM, Zeitler PS. Insulin Resistance of Puberty. *Curr Diab Rep.* 2016; 16:64. [PubMed: 27179965]
3. Hernandez TL. Glycemic targets in pregnancies affected by diabetes: historical perspective and future directions. *Curr Diab Rep.* 2015; 15:565. [PubMed: 25398204]
4. Mestman JH. Historical notes on diabetes and pregnancy. *The Endocrinologist.* 2002; 12:224–42.
5. Freinkel N. Banting Lecture 1980. Of pregnancy and progeny. *Diabetes.* 1980; 29:1023–35. [PubMed: 7002669]
6. Devlieger R, Benhalima K, Damm P, Van Assche A, Mathieu C, Mahmood T, et al. Maternal obesity in Europe: where do we stand and how to move forward?: A scientific paper commissioned by the European Board and College of Obstetrics and Gynaecology (EBCOG). *Eur J Obstet Gynecol Reprod Biol.* 2016; 201:203–8. [PubMed: 27160501]
7. Flegal KM, Kruszon-Moran D, Carroll MD, Fryar CD, Ogden CL. Trends in Obesity Among Adults in the United States, 2005 to 2014. *JAMA.* 2016; 315:2284–91. [PubMed: 27272580]
8. Ryan EA. Diagnosing gestational diabetes. *Diabetologia.* 2011; 54:480–6. [PubMed: 21203743]
9. Metzger BE, Gabbe SG, Persson B, Buchanan TA, Catalano PA, Damm P, et al. International association of diabetes and pregnancy study groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy. *Diabetes Care.* 2010; 33:676–82. [PubMed: 20190296]
10. Sacks DA, Hadden DR, Maresh M, Deerochanawong C, Dyer AR, Metzger BE, et al. Frequency of gestational diabetes mellitus at collaborating centers based on IADPSG consensus panel-recommended criteria: the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) Study. *Diabetes Care.* 2012; 35:526–8. [PubMed: 22355019]
11. Westman EC, Yancy WS Jr, Humphreys M. Dietary treatment of diabetes mellitus in the pre-insulin era (1914–1922). *Perspect Biol Med.* 2006; 49:77–83. [PubMed: 16489278]
12. Jovanovic-Peterson L, Peterson CM. Dietary manipulation as a primary treatment strategy for pregnancies complicated by diabetes. *J Am Coll Nutr.* 1990; 9:320–5. [PubMed: 2212389]
13. Hernandez TL. Nutrition Therapy in Gestational Diabetes: The Case for Complex Carbohydrates. *Diabetes Spectrum.* 2016

14. Metzger BE, Buchanan TA, Coustan D, de Leiva A, Dunger DB, Hadden DR, et al. Summary and recommendations of the fifth international workshop-conference on Gestational Diabetes Mellitus. *Diabetes Care*. 2007; 30:S251–S60. [PubMed: 17596481]
15. Han S, Middleton P, Shepherd E, Van Ryswyk E, Crowther CA. Different types of dietary advice for women with gestational diabetes mellitus. *Cochrane Database Syst Rev*. 2017; 2:CD009275. [PubMed: 28236296]
16. Hernandez TL, Anderson MA, Chartier-Logan C, Friedman JE, Barbour LA. Strategies in the nutritional management of gestational diabetes. *Clin Obstet Gynecol*. 2013; 56:803–15. [PubMed: 24047934]
17. Barrett HL, Dekker NM, McIntyre HD, Callaway LK. Normalizing metabolism in diabetic pregnancy: is it time to target lipids? *Diabetes Care*. 2014; 37:1484–93. [PubMed: 24757231]
18. Harmon KA, Gerard L, Jensen DR, Kealey EH, Hernandez TL, Reece MS, et al. Continuous Glucose Profiles in Obese and Normal-Weight Pregnant Women on a Controlled Diet: Metabolic determinants of fetal growth. *Diabetes Care*. 2011; 34:2198–204. [PubMed: 21775754]
19. Barbour LA, Farabi SS, Friedman JE, Hirsch NM, Reece MS, Van Pelt RE, Hernandez TL. Fasting and postprandial triglycerides predict newborn fat in obese women in early pregnancy. *Diabetes Care*. Under Review.
20. Olmos PR, Rigotti A, Busso D, Berkowitz L, Santos JL, Borzone GR, et al. Maternal hypertriglyceridemia: A link between maternal overweight-obesity and macrosomia in gestational diabetes. *Obesity (Silver Spring)*. 2014
21. Schaefer-Graf UM, Graf K, Kulbacka I, Kjos SL, Dudenhausen J, Vetter K, et al. Maternal lipids as strong determinants of fetal environment and growth in pregnancies with gestational diabetes mellitus. *Diabetes Care*. 2008; 31:1858–63. [PubMed: 18606978]
22. Vrijkotte TG, Algera SJ, Brouwer IA, van Eijnsden M, Twickler MB. Maternal triglyceride levels during early pregnancy are associated with birth weight and postnatal growth. *J Pediatr*. 2011; 159:736–42. e1. [PubMed: 21705016]
23. Di Cianni G, Miccoli R, Volpe L, Lencioni C, Ghio A, Giovannitti MG, et al. Maternal triglyceride levels and newborn weight in pregnant women with normal glucose tolerance. *Diabet Med*. 2005; 22:21–5.
24. Whyte K, Kelly H, O'Dwyer V, Gibbs M, O'Higgins A, Turner MJ. Offspring birth weight and maternal fasting lipids in women screened for gestational diabetes mellitus (GDM). *Eur J Obstet Gynecol Reprod Biol*. 2013; 170:67–70. [PubMed: 23809999]
25. Liu B, Geng H, Yang J, Zhang Y, Deng L, Chen W, et al. Early pregnancy fasting plasma glucose and lipid concentrations in pregnancy and association to offspring size: a retrospective cohort study. *BMC Pregnancy Childbirth*. 2016; 16:56. [PubMed: 26988100]
26. Mudd LM, Holzman CB, Evans RW. Maternal mid-pregnancy lipids and birthweight. *Acta Obstet Gynecol Scand*. 2015; 94:852–60. [PubMed: 25912426]
27. Jin WY, Lin SL, Hou RL, Chen XY, Han T, Jin Y, et al. Associations between maternal lipid profile and pregnancy complications and perinatal outcomes: a population-based study from China. *BMC Pregnancy Childbirth*. 2016; 16:60. [PubMed: 27000102]
28. Eslamian L, Akbari S, Marsoosi V, Jamal A. Effect of different maternal metabolic characteristics on fetal growth in women with gestational diabetes mellitus. *Iran J Reprod Med*. 2013; 11:325–34. [PubMed: 24639763]
29. Small P, Brand-Miller JC. From complex carbohydrate to glycemic index: Tracing the controversy. *Nutrition Today*. 2009; 44:236–43.
30. Di Cianni G, Miccoli R, Volpe L, Lencioni C, Del Prato S. Intermediate metabolism in normal pregnancy and in gestational diabetes. *Diabetes Metab Res Rev*. 2003; 19:259–70. [PubMed: 12879403]
31. Buchanan TA, Xiang AH. Gestational diabetes mellitus. *J Clin Invest*. 2005; 115:485–91. [PubMed: 15765129]
32. Di Cianni G, Miccoli R, Volpe L, Lencioni C, Del Prato S. Intermediate metabolism in normal pregnancy and in gestational diabetes. *Diabetes Metab Res Rev*. 2003; 19:259–70. [PubMed: 12879403]

33. Butte NF. Carbohydrate and lipid metabolism in pregnancy: normal compared with gestational diabetes mellitus. *Am J Clin Nutr.* 2000; 71:1256S–61S. [PubMed: 10799399]
34. Kjos SL. Postpartum care of the woman with diabetes. *Clin Obstet Gynecol.* 2000; 43:75–86. [PubMed: 10694990]
35. Star J, Coustan DR. Overview of gestational diabetes. In: Lee RV, Rosene-Montella K, Barbour LA, Garner PR, Keely E, editors *Medical care of the pregnant patient.* Philadelphia: American College of Physicians; 2000. 235–48.
36. Hernandez TLF, J E, Barbour LA. Insulin Resistance in Pregnancy: Implications for Mother and Offspring. In: Zeitler PN, K J, editors *Insulin Resistance: Childhood Precursors to Adult Disease.* 2. Springer; 2018. in-press
37. Buchanan TA, Xiang AH. Gestational diabetes mellitus. *J Clin Invest.* 2005; 115:485–91. [PubMed: 15765129]
38. Sivan E, Homko CJ, Whittaker PG, Reece EA, Chen X, Boden G. Free fatty acids and insulin resistance during pregnancy. *J Clin Endocrinol Metab.* 1998; 83:2338–42. [PubMed: 9661605]
39. Kim SY, England L, Wilson HG, Bish C, Satten GA, Dietz P. Percentage of gestational diabetes mellitus attributable to overweight and obesity. *Am J Public Health.* 2010; 100:1047–52. [PubMed: 20395581]
40. Powe CE, Allard C, Battista MC, Doyon M, Bouchard L, Ecker JL, et al. Heterogeneous Contribution of Insulin Sensitivity and Secretion Defects to Gestational Diabetes Mellitus. *Diabetes Care.* 2016; 39:1052–5. [PubMed: 27208340]
41. Hernandez TL, van Pelt RE, Anderson MA, Reece MS, Reynolds RM, de la Houssaye BA, et al. Women With Gestational Diabetes Mellitus Randomized to a Higher-Complex Carbohydrate/Low-Fat Diet Manifest Lower Adipose Tissue Insulin Resistance, Inflammation, Glucose, and Free Fatty Acids: A Pilot Study. *Diabetes Care.* 2016; 39:39–42. [PubMed: 26223240]
42. Chen R, Yogev Y, Ben Haroush A, Jovanovic L, Hod M, Phillip M. Continuous glucose monitoring for the evaluation and improved control of gestational diabetes mellitus. *J Matern Fetal Neonatal Med.* 2003; 14:256–60. [PubMed: 14738172]
43. Carreiro MP, Lauria MW, Naves GN, Miranda PA, Leite RB, Rajao KM, et al. Seventy two-hour glucose monitoring profiles in mild gestational diabetes mellitus: differences from healthy pregnancies and influence of diet counseling. *Eur J Endocrinol.* 2016; 175:201–9. [PubMed: 27466287]
44. Ryckman KK, Spracklen CN, Smith CJ, Robinson JG, Saftlas AF. Maternal lipid levels during pregnancy and gestational diabetes: a systematic review and meta-analysis. *BJOG.* 2015; 122:643–51. [PubMed: 25612005]
45. Hernandez TL, van Pelt RE, Anderson MA, Daniels LJ, West NA, Donahoo WT, et al. A higher-complex carbohydrate diet in gestational diabetes mellitus achieves glucose targets and lowers postprandial lipids: a randomized crossover study. *Diabetes Care.* 2014; 37:1254–62. [PubMed: 24595632]
46. Heerwagen MJR, Gumina DL, Hernandez TL, Van Pelt RE, Kramer AW, Janssen RC, Jensen DR, Powell TL, Friedman JE, Winn VD, Barbour LA. Placental lipoprotein lipase activity is positively associated with newborn adiposity. *Placenta.* 2018 in-press.
47. Augustin LS, Kendall CW, Jenkins DJ, Willett WC, Astrup A, Barclay AW, et al. Glycemic index, glycemic load and glycemic response: An International Scientific Consensus Summit from the International Carbohydrate Quality Consortium (ICQC). *Nutr Metab Cardiovasc Dis.* 2015; 25:795–815. [PubMed: 26160327]
48. Moses RG, Brand-Miller JC. The use of a low glycaemic index diet in pregnancy: an evolving treatment paradigm. *Diabetes Res Clin Pract.* 2011; 91:13–4. [PubMed: 21109323]
49. Aziz A, Dumais L, Barber J. Health Canada's evaluation of the use of glycemic index claims on food labels. *Am J Clin Nutr.* 2013; 98:269–74. [PubMed: 23761481]
50. Agriculture USDoHaHSAUSDo. 2015– 2020 Dietary guidelines for Americans. 2015
51. Standardization IOF. Determination of glycaemic index and recommendation for food classification. International Organization for Standardization; ISO 26642:2010 ed2010
52. Eckel RH. Role of glycemic index in the context of an overall heart-healthy diet. *JAMA.* 2014; 312:2508–9. [PubMed: 25514301]

53. Lawson EJ, Rajaram S. A transformed pregnancy: The psychosocial consequences of gestational diabetes. *Sociol Health Illn.* 1994; 16:536–62.
54. Draffin CR, Alderdice FA, McCance DR, Maresh M, Harper Md, Consultant Physician R. McSorley O, et al. Exploring the needs, concerns and knowledge of women diagnosed with gestational diabetes: A qualitative study. *Midwifery.* 2016; 40:141–7. [PubMed: 27553869]
55. Hui AL, Sevenhuysen G, Harvey D, Salamon E. Stress and anxiety in women with gestational diabetes during dietary management. *Diabetes Educ.* 2014; 40:668–77. [PubMed: 24874692]
56. Smith-Morris CM. Diagnostic controversy: gestational diabetes and the meaning of risk for pima Indian women. *Med Anthropol.* 2005; 24:145–77. [PubMed: 16019569]
57. Hui AL, Sevenhuysen G, Harvey D, Salamon E. Food choice decision-making by women with gestational diabetes. *Can J Diabetes.* 2014; 38:26–31. [PubMed: 24485210]
58. Ge L, Wikby K, Rask M. 'Is gestational diabetes a severe illness?' exploring beliefs and self-care behaviour among women with gestational diabetes living in a rural area of the south east of China. *Aust J Rural Health.* 2016; 24:378–84. [PubMed: 27087496]
59. Teixeira PJ, Carraca EV, Marques MM, Rutter H, Oppert JM, De BI, et al. Successful behavior change in obesity interventions in adults: a systematic review of self-regulation mediators. *BMC Med.* 2015; 13:84. [PubMed: 25907778]
60. Hernandez TL. Higher-complex carbohydrate diets in gestational diabetes. In: Rajendram VBPVRPR. , editor *Nutrition and diet in maternal diabetes: An Evidence-Based Approach.* New York, NY: Springer; 2018.
61. Barbour LA, McCurdy CE, Hernandez TL, Kirwan JP, Catalano PM, Friedman JE. Cellular mechanisms for insulin resistance in normal pregnancy and gestational diabetes. *Diabetes Care.* 2007; 30(Suppl 2):S112–9. [PubMed: 17596458]
62. Sivan E, Homko CJ, Whittaker PG, Reece EA, Chen X, Boden G. Free fatty acids and insulin resistance during pregnancy. *J Clin Endocrinol Metab.* 1998; 83:2338–42. [PubMed: 9661605]
63. Desrosiers TA, Siega-Riz AM, Mosley BS, Meyer RE. National Birth Defects Prevention S. Low carbohydrate diets may increase risk of neural tube defects. *Birth Defects Res.* 2018
64. Hernandez TL, Sutherland JP, Wolfe P, Allian-Sauer M, Capell WH, Talley ND, et al. Lack of suppression of circulating free fatty acids and hypercholesterolemia during weight loss on a high-fat, low-carbohydrate diet. *Am J Clin Nutr.* 2010; 91:578–85. [PubMed: 20107198]
65. Friedman JE. Obesity and Gestational Diabetes Mellitus Pathways for Programming in Mouse, Monkey, and Man-Where Do We Go Next? The 2014 Norbert Freinkel Award Lecture. *Diabetes Care.* 2015; 38:1402–11. [PubMed: 26207051]
66. Magee MS, Knopp RH, Benedetti TJ. Metabolic effects of 1200-kcal diet in obese pregnant women with gestational diabetes. *Diabetes.* 1990; 39:234–40. [PubMed: 2227131]
67. Holme AM, Roland MC, Lorentzen B, Michelsen TM, Henriksen T. Placental glucose transfer: a human in vivo study. *PLoS One.* 2015; 10:e0117084. [PubMed: 25680194]
68. Medicine Io. *Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids.* Washington, DC: The National Academies Press; 2005.
69. Hanson MA, Gluckman PD. Early developmental conditioning of later health and disease: physiology or pathophysiology? *Physiol Rev.* 2014; 94:1027–76. [PubMed: 25287859]
70. Barker DJ, Thornburg KL. The obstetric origins of health for a lifetime. *Clin Obstet Gynecol.* 2013; 56:511–9. [PubMed: 23787713]
71. Wolever TM. Is glycaemic index (GI) a valid measure of carbohydrate quality? *Eur J Clin Nutr.* 2013; 67:522–31. [PubMed: 23403873]
72. Nicklas JM, Barbour LA. Optimizing Weight for Maternal and Infant Health - Tenable, or Too Late? *Expert Rev Endocrinol Metab.* 2015; 10:227–42. [PubMed: 26442123]
73. McFarland MB, Langer O, Conway DL, Berkus MD. Dietary therapy for gestational diabetes: how long is long enough? *Obstet Gynecol.* 1999; 93:978–82. [PubMed: 10362166]
74. Barnes RA, Wong T, Ross GP, Jalaludin BB, Wong VW, Smart CE, et al. A novel validated model for the prediction of insulin therapy initiation and adverse perinatal outcomes in women with gestational diabetes mellitus. *Diabetologia.* 2016; 59:2331–8. [PubMed: 27393136]

75. Nolan CJ. Improved glucose tolerance in gestational diabetic women on a low fat, high unrefined carbohydrate diet. *Aust N Z J Obstet Gynaecol.* 1984; 24:174–7. [PubMed: 6393945]
76. Cypriak K, Pertynska-Marczewska M, Szymczak W, Wilcynski J, Lewinski A. Evaluation of metabolic control in women with gestational diabetes mellitus by the continuous glucose monitoring system: a pilot study. *Endocr Pract.* 2006; 12:245–50. [PubMed: 16772194]
77. Asemi Z, Samimi M, Tabassi Z, Sabihi SS, Esmailzadeh A. A randomized controlled clinical trial investigating the effect of DASH diet on insulin resistance, inflammation, and oxidative stress in gestational diabetes. *Nutrition.* 2013; 29:619–24. [PubMed: 23466048]
78. Asemi Z, Tabassi Z, Samimi M, Fahiminejad T, Esmailzadeh A. Favourable effects of the Dietary Approaches to Stop Hypertension diet on glucose tolerance and lipid profiles in gestational diabetes: a randomised clinical trial. *Br J Nutr.* 2013; 109:2024–30. [PubMed: 23148885]
79. Roden M, Price TB, Perseghin G, Petersen KF, Rothman DL, Cline GW, et al. Mechanism of free fatty acid-induced insulin resistance in humans. *J Clin Invest.* 1996; 97:2859–65. [PubMed: 8675698]
80. Gynecologists ACoOa. ACOG Practice Bulletin: Gestational Diabetes Mellitus. Washington, DC: 2013. 1–11.
81. Frayn K. *Metabolic regulation: A human perspective.* 2. Oxford, UK: Blackwell Science; 2003.
82. Moreno-Castilla C, Hernandez M, Bergua M, Alvarez MC, Arce MA, Rodriguez K, et al. Low-Carbohydrate Diet for the Treatment of Gestational Diabetes: A randomized controlled trial. *Diabetes Care.* 2013
83. Louie JC, Markovic TP, Perera N, Foote D, Petocz P, Ross GP, et al. A randomized controlled trial investigating the effects of a low-glycemic index diet on pregnancy outcomes in gestational diabetes mellitus. *Diabetes Care.* 2011; 34:2341–6. [PubMed: 21900148]
84. Medicine Io, Council NR. Weight gain during pregnancy: Reexamining the guidelines. In: Rasmussen KM, Yaktine AL, editors Committee to reexamine IOM pregnancy weight gain guidelines. National Academies Press; Washington, D.C: 2009. 1–250.
85. Asemi Z, Samimi M, Tabassi Z, Esmailzadeh A. The effect of DASH diet on pregnancy outcomes in gestational diabetes: a randomized controlled clinical trial. *Eur J Clin Nutr.* 2014; 68:490–5. [PubMed: 24424076]
86. Major CA, Henry MJ, de Veciana M, Morgan MA. The effects of carbohydrate restriction in patients with diet-controlled gestational diabetes. *Obstet Gynecol.* 1998; 91:600–4. [PubMed: 9540949]
87. Moses RG, Barker M, Winter M, Petocz P, Brand-Miller JC. Can a low-glycemic index diet reduce the need for insulin in gestational diabetes mellitus? A randomized trial. *Diabetes Care.* 2009; 32:996–1000. [PubMed: 19279301]
88. Brumbaugh DE, Tarse P, Cree-Green M, Fenton LZ, Brown M, Scherzinger A, et al. Intrahepatic Fat Is Increased in the Neonatal Offspring of Obese Women with Gestational Diabetes. *J Pediatr.* 2012
89. Brumbaugh DE, Friedman JE. Developmental origins of nonalcoholic fatty liver disease. *Pediatr Res.* 2014; 75:140–7. [PubMed: 24192698]
90. McRorie JW Jr, McKeown NM. Understanding the Physics of Functional Fibers in the Gastrointestinal Tract: An Evidence-Based Approach to Resolving Enduring Misconceptions about Insoluble and Soluble Fiber. *J Acad Nutr Diet.* 2017; 117:251–64. [PubMed: 27863994]
91. de Carvalho CM, de Paula TP, Viana LV, Machado VM, de Almeida JC, Azevedo MJ. Plasma glucose and insulin responses after consumption of breakfasts with different sources of soluble fiber in type 2 diabetes patients: a randomized crossover clinical trial. *Am J Clin Nutr.* 2017; 106:1238–45. [PubMed: 28855225]
92. Bao J, Atkinson F, Petocz P, Willett WC, Brand-Miller JC. Prediction of postprandial glycemia and insulinemia in lean, young, healthy adults: glycemic load compared with carbohydrate content alone. *Am J Clin Nutr.* 2011; 93:984–96. [PubMed: 21325437]
93. Brand-Miller JC, Buyken AE. The glycemic index issue. *Curr Opin Lipidol.* 2012; 23:62–7. [PubMed: 22157060]

94. Cypryk K, Kaminska P, Kosinski M, Pertynska-Marczewska M, Lewinski A. A comparison of the effectiveness, tolerability and safety of high and low carbohydrate diets in women with gestational diabetes. *Endokrynol Pol.* 2007; 58:314–9. [PubMed: 18058723]
95. Hu ZG, Tan RS, Jin D, Li W, Zhou XY. A low glycemic index staple diet reduces postprandial glucose values in Asian women with gestational diabetes mellitus. *J Investig Med.* 2014; 62:975–9.
96. Pastor-Villaescusa B, Rangel-Huerta OD, Aguilera CM, Gil A. A Systematic Review of the Efficacy of Bioactive Compounds in Cardiovascular Disease: Carbohydrates, Active Lipids and Nitrogen Compounds. *Ann Nutr Metab.* 2015; 66:168–81. [PubMed: 26045206]
97. Wei J, Heng W, Gao J. Effects of Low Glycemic Index Diets on Gestational Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Clinical Trials. *Medicine (Baltimore).* 2016; 95:e3792. [PubMed: 27258511]
98. Zhang R, Han S, Chen GC, Li ZN, Silva-Zolezzi I, Pares GV, et al. Effects of low-glycemic-index diets in pregnancy on maternal and newborn outcomes in pregnant women: a meta-analysis of randomized controlled trials. *Eur J Nutr.* 2016
99. Grant SM, Wolever TM, O'Connor DL, Nisenbaum R, Josse RG. Effect of a low glycaemic index diet on blood glucose in women with gestational hyperglycaemia. *Diabetes Res Clin Pract.* 2011; 91:15–22. [PubMed: 21094553]
100. Walsh JM, McGowan CA, Mahony R, Foley ME, McAuliffe FM. Low glycaemic index diet in pregnancy to prevent macrosomia (ROLO study): randomised control trial. *BMJ.* 2012; 345:e5605. [PubMed: 22936795]
101. McGowan CA, Walsh JM, Byrne J, Curran S, McAuliffe FM. The influence of a low glycemic index dietary intervention on maternal dietary intake, glycemic index and gestational weight gain during pregnancy: a randomized controlled trial. *Nutr J.* 2013; 12:140. [PubMed: 24175958]
102. Markovic TP, Muirhead R, Overs S, Ross GP, Louie JC, Kizirian N, et al. Randomized Controlled Trial Investigating the Effects of a Low-Glycemic Index Diet on Pregnancy Outcomes in Women at High Risk of Gestational Diabetes Mellitus: The GI Baby 3 Study. *Diabetes Care.* 2016; 39:31–8. [PubMed: 26185283]
103. Kizirian NV, Kong Y, Muirhead R, Brodie S, Garnett SP, Petocz P, et al. Effects of a low-glycemic index diet during pregnancy on offspring growth, body composition, and vascular health: a pilot randomized controlled trial. *Am J Clin Nutr.* 2016; 103:1073–82. [PubMed: 26936333]
104. Louie JC, Buyken AE, Brand-Miller JC, Flood VM. The link between dietary glycemic index and nutrient adequacy. *Am J Clin Nutr.* 2012; 95:694–702. [PubMed: 22258270]
105. Reece EA, Hagay Z, Gay LJ, T OC, Degennaro N, Homko CJ, et al. A randomized clinical trial of a fiber-enriched diabetic diet vs. the standard American Diabetes Association-recommended diet in the management of diabetes mellitus in pregnancy. *J Matern Fetal Invest.* 1995; 5:8–12.
106. Popkin BM, Adair LS, Ng SW. Global nutrition transition and the pandemic of obesity in developing countries. *Nutr Rev.* 2012; 70:3–21. [PubMed: 22221213]
107. Valentini R, Dalfra MG, Masin M, Barison A, Marialisa M, Pegoraro E, et al. A pilot study on dietary approaches in multiethnicity: two methods compared. *Int J Endocrinol.* 2012; 2012:985136. [PubMed: 22505892]
108. Thompson SV, Winham DM, Hutchins AM. Bean and rice meals reduce postprandial glycemic response in adults with type 2 diabetes: a cross-over study. *Nutr J.* 2012; 11:23. [PubMed: 22494488]
109. Lee YM, Kim SA, Lee IK, Kim JG, Park KG, Jeong JY, et al. Effect of a Brown Rice Based Vegan Diet and Conventional Diabetic Diet on Glycemic Control of Patients with Type 2 Diabetes: A 12-Week Randomized Clinical Trial. *PLoS One.* 2016; 11:e0155918. [PubMed: 27253526]
110. Narayanan J, Sanjeevi V, Rohini U, Trueman P, Viswanathan V. Postprandial glycaemic response of foxtail millet dosa in comparison to a rice dosa in patients with type 2 diabetes. *Indian J Med Res.* 2016; 144:712–7. [PubMed: 28361824]
111. Sohal T, Sohal P, King-Shier KM, Khan NA. Barriers and Facilitators for Type-2 Diabetes Management in South Asians: A Systematic Review. *PLoS One.* 2015; 10:e0136202. [PubMed: 26383535]

112. Kam J, Puranik S, Yadav R, Manwaring HR, Pierre S, Srivastava RK, et al. Dietary Interventions for Type 2 Diabetes: How Millet Comes to Help. *Front Plant Sci.* 2016; 7:1454. [PubMed: 27729921]
113. Catalano PM, Farrell K, Thomas A, Huston-Presley L, Mencin P, de Mouzon SH, et al. Perinatal risk factors for childhood obesity and metabolic dysregulation. *Am J Clin Nutr.* 2009; 90:1303–13. [PubMed: 19759171]
114. Mulligan CM, Friedman JE. Maternal modifiers of the infant gut microbiota: metabolic consequences. *J Endocrinol.* 2017; 235:R1–R12. [PubMed: 28751453]
115. Azad MB, Abou-Setta AM, Chauhan BF, Rabbani R, Lys J, Copstein L, et al. Nonnutritive sweeteners and cardiometabolic health: a systematic review and meta-analysis of randomized controlled trials and prospective cohort studies. *CMAJ.* 2017; 189:E929–E39. [PubMed: 28716847]




Figure 1.

The impact of rigid restriction and less-restrictive approaches on maternal metabolism in GDM. In environments promoting over-nutrition and physical inactivity, with rigid carbohydrate restriction comes a tendency to replace carbohydrate energy with calories from fat. Higher total and saturated fat intake amplify maternal adipose tissue lipolysis, worsening FFA and dampening insulin signaling, leading to higher systemic and hepatic insulin resistance (IR). In maternal circulation, IR results in higher levels of free fatty acids (FFA), glucose, and amino acids (AA) available to the placenta and fetus. Higher inflammation linked to adipose tissue and the gut microbiome with IR promote nutrient shunting through placental nutrient transporters, promoting fetal overgrowth and excess fat accretion. Maternal obesity and GDM has been associated with increased intrahepatic lipid accumulation[88], higher birthweight and newborn adiposity, all risk factors for childhood obesity. Modification of maternal metabolism using a less carbohydrate-restrictive approach that liberalizes higher-quality complex carbohydrates in combination with lower fat may attenuate maternal IR and promote appropriate fetal growth, setting the stage for lifetime health and lower obesity risk. (TG = triglycerides; pLPL = placental lipoprotein lipase; GLUT-1 = glucose transporter; %BF = percent body fat)

Table 1

Local/Traditional foods from varied geographical regions that qualify for a less carbohydrate-restricted dietary approach in GDM.

Geographical region	Examples of traditional foods that qualify for less restricted GDM Nutrition therapy approach
North America	<ul style="list-style-type: none"> - Whole grain breads, pasta, brown or parboiled rice, oats - Vegetables, fruits, beans, lentils - Low-fat dairy, lean poultry and fish - Occasional meats, cheese and nuts
Latin America	<ul style="list-style-type: none"> - Whole grains like amaranth, maize, quinoa, brown rice - Vegetables, fruits, beans - Lean poultry, fish, low-fat dairy - Occasional meats, nuts and cheese
Mediterranean Region	<ul style="list-style-type: none"> - Whole grain bread/pasta, brown rice, couscous - Vegetables, fruits, beans, lentils - White fish, lean poultry, low-fat dairy - Occasional nuts, cheese, meats and shellfish
Africa	<ul style="list-style-type: none"> - Whole grains like millets, sorghum, teff, parboiled rice - Vegetables, fruits, roots, tubers, beans - Fish, eggs, poultry - Occasional meats and dairy
South Asia	<ul style="list-style-type: none"> - Whole wheat, millets, barley, rye, buckwheat, parboiled rice, wheat rotis - Vegetables, roots, tubers, fruits - Beans, lentils, dals, low-fat dairy, lean poultry, fish - Occasional meats, nuts and cottage cheese (paneer)
East Asia	<ul style="list-style-type: none"> - Noodles and brown rice - Soybeans, fish, seafood, vegetables, wild plants, seaweed, mushrooms - Occasional lean meats, shellfish, dairy